LEADER 03652nam 2200949z- 450 001 9910557353103321 005 20231214133423.0 035 $a(CKB)5400000000042359 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77096 035 $a(EXLCZ)995400000000042359 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aProteases?From Basic Structure to Function to Drug Design as Targeted Therapy 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (93 p.) 311 $a3-0365-2575-0 311 $a3-0365-2574-2 330 $aIn the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibition strategies are one of the fastest expanding areas in the field of of drugs that show considerable promise. This Special Issue will focus on the recent advances in the discovery and development of protease inhibitors, covering the synthesis of protease inhibitors, the design of new chemical entities acting as inhibitors of special/particular types of proteases, and their mode of actions (Frolova et al. 2020; Slapak et al. 2020; Künnapuu et al. 2021). In addition, the new applications of these interesting compounds/biomolecules and their limitations have been discussed and described (Wang et al. 2020; Barto?ová-Sojková et al. 2021). 606 $aResearch & information: general$2bicssc 610 $aMMP 610 $aMMP2 610 $aMMP9 610 $aMMP7 610 $aMMP14 610 $amatrix metalloproteases 610 $aPDAC 610 $apancreatic cancer 610 $aBowman?Birk inhibitor 610 $aranacyclin 610 $atrypsin inhibitor 610 $astructure?activity relationship 610 $asynergistic effect 610 $aGentamicin 610 $amatrix metalloproteinase 610 $aextracellular matrix 610 $anuclei 610 $acancer 610 $aapoptosis 610 $aimmune response 610 $acysteine protease inhibitor 610 $astefin 610 $asignal peptide 610 $aparasite 610 $aphylogenetic analysis 610 $adiversification 610 $aprotein structure 610 $avascular endothelial growth factors (VEGFs) 610 $aVEGF-A 610 $aPlGF 610 $aVEGF-B 610 $aVEGF-C 610 $aVEGF-D 610 $aangiogenesis 610 $alymphangiogenesis 610 $aCCBE1 610 $aproteases 610 $aADAMTS3 610 $aplasmin 610 $acathepsin D 610 $aKLK3 610 $aprostate-specific antigen (PSA) 610 $athrombin 610 $awound healing 610 $ametastasis 610 $aproteolytic activation 610 $avascular biology 610 $alymphedema 615 7$aResearch & information: general 700 $aKwok$b Hang Fai$4edt$01310431 702 $aShaw$b Christopher$4edt 702 $aWalker$b Brian$4edt 702 $aKwok$b Hang Fai$4oth 702 $aShaw$b Christopher$4oth 702 $aWalker$b Brian$4oth 906 $aBOOK 912 $a9910557353103321 996 $aProteases?From Basic Structure to Function to Drug Design as Targeted Therapy$93029804 997 $aUNINA